Irvine drug maker Allergan Inc. said it sees higher than expected 2006 sales of $2.8 billion to $2.9 billion but said first-quarter results could come in slightly below analysts’ expectations.
For the current quarter, Allergan said it sees sales of $600 million and $610 million. Wall Street was expecting $617 million.
First-quarter net income could come in at $108 million, versus the $109 million analysts were looking for.
For the year, Allergan said it expects net income of up to $483 million, including stock expenses. Wall Street was expecting $479 million.
2006’s revenue should include about $385 million in sales from recently acquired Inamed Corp. of Santa Barbara, a maker of cosmetic skin products, breast implants and obesity products.
